Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026 Press Release Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026February 10, 2026 – release at 7:30 am Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that phase 3 clinical study results, including two podium presentations, will be delivered at the upcoming American Glaucoma Society (AGS) Annual Meeting 2026 (February 19-22, 2026, Rancho Mirage, C...
Nicox : Présentation des données des études de Phase 3 de NCX 470 au congrès annuel 2026 de l’American Glaucoma Society (AGS) Communiqué de presseNicox : Présentation des données des études de Phase 3 de NCX 470 au congrès annuel 2026 de l’American Glaucoma Society (AGS) 10 février 2026 – publication à 7H30Sophia Antipolis, FranceNicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une société internationale spécialisée en ophtalmologie, annonce aujourd’hui que les résultats des études de phase 3, dont deux présentations orales sur podium, seront présentés lors du proch...
International Petroleum Corporation Announces 2025 Year-End Financial and Operational Results and 2026 Budget, Reserves and Guidance International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) today released its financial and operating results and related management’s discussion and analysis (MD&A) for the three months and year ended December 31, 2025. IPC is also pleased to announce its 2026 budget, with the focus on finalizing the development of the Blackrod Phase 1 project in Canada. As previously announced, IPC achieved first steam injection at the Blackro...
VIEL ET COMPAGNIE : Chiffre d’affaires de 1 266,9 millions d’euros sur l’année 2025 en croissance de 7,4% à cours de change courants -Croissance de 10,7% du chiffre d’affaires à cours de change constants En 2025, le Groupe a évolué dans un environnement macroéconomique complexe marqué par la transition des politiques monétaires des principales banques centrales vers un assouplissement mesuré et par une intensification des tensions commerciales internationales. VIEL & Cie enregistre une forte croissance de son activité en 2025 avec un chiffre d’affaires consolidé de 1 266,9 millions d’e...
A director at IOI Properties Group Berhad bought 1,418,200 shares at 3.326MYR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
A director at Danish Power Ltd bought 3,750 shares at 631.000INR and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
A director at Arab Co. For Asset Management And Development bought/sold 6,250,000 shares at 0.000EGP and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's di...
A director at Valmore Holding sold/bought 100,000 shares at 0.000USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
A director at Techno Medica Co Ltd sold 300,000 shares at 2,249.000JPY and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Moody's Ratings ("Moody's") has affirmed the B2 Corporate Family Rating (CFR) and the B2-PD Probability of Default Rating (PDR) for ARC Falcon I Inc. ("Arclin"). We have also assigned a B2 rating to the company's new seven year $1.225 billion senior secured first lien term loan, new seven year $1.5 ...
TGS announces Engagement Phase 9 in the Gulf of America OSLO, Norway (10 February 2026) – TGS, a global provider of energy data and intelligence, in strategic collaboration with SLB, today announced the launch of Engagement 9, the latest phase of the companies’ Ocean Bottom Node (OBN) multi-client campaign in the Gulf of America. Commencing earlier this month, Engagement 9 covers 161 OCS blocks in the Walker Ridge protraction area, one of the Gulf of America’s most prolific deepwater provinces. This new dataset is expected to deliver step change improvements in subsurface illumination acro...
Sale of a subsidiary of EfTEN Real Estate Fund AS in Latvia EfTEN Real Estate Fund AS is selling the DSV logistics property in Riga at 500 thousands euros above the balance sheet value. The transaction is structured as a share deal selling the 100% subsidiary EfTEN Krustpils SIA (registration number with the Latvian Commercial Register 40103921371), for which the fund has entered into a sale and purchase agreement with the Latvian company ROLANDS S, SIA (registration number with the Latvian Commercial Register 40103130964). The activities of EfTEN Krustpils SIA are related to the ownership ...
Hexagon Purus ASA: Results for the fourth quarter 2025 Key developments in Q4 2025 and after balance sheet date: Revenue of NOK 468 million in the fourth quarter of 2025, 18% higher compared to same period last year. FY 2025 revenue was NOK 1,144 million, down 39% compared to FY 2024;EBITDA of NOK -99 million (-21% margin) in the fourth quarter of 2025, compared to NOK -104 million (-26% margin) in the same period last year. EBITDA in the fourth quarter of 2025 included NOK 76 million of inventory write-downs, warranty provisions, bad debt expense and restructuring costs (“Items Affecting ...
Unaudited financial results of LHV Group for Q4 and 12 months of 2025 At the end of 2025, LHV Group’s deposit and loan portfolio volumes both demonstrated very strong growth. In 2025, LHV Group’s revenue dynamics were influenced by changes in the interest rate environment throughout the year, which put pressure on interest income, while strong competition in the deposit market increased interest expenses. Strong growth in customer activity and fee and commission income helped to partially offset the decline in net interest income. In Q4, net interest income already showed growth compared to...
EfTEN Real Estate Fund AS-i tütarettevõtte müük Lätis EfTEN Real Estate Fund AS müüb DSV logistikahoone Riias bilansilisest väärtusest ligakaudu 500 tuhande euro võrra kõrgema hinnaga. Tehing on struktureeritud tütarettevõtte EfTEN Krustpils SIA (registreerimisnumber Läti ettevõtteregistris 40103921371) 100%-lise osaluse müügina, milleks on fond sõlminud võlaõigusliku müügilepingu Läti ettevõtte ROLANDS S, SIA-ga (registreerimisnumber Läti ettevõtteregistris 40103130964). EfTEN Krustpils SIA tegevus on seotud Riias Krustpils 31 asuva kinnistu (DSV logistikahoone) omamise ja majandamisega. T...
Wereldhave Full-year results 2025 Direct result 2025 at € 1.86 per share, above guidance of € 1.80-1.85Occupancy rate at 98%, highest since 2013Like-for-like rental growth of +6%, driven by improved Dutch retail market and focus on other incomeDisposal of Dutch FSC Sterrenburg (€ 60m) at book value in December 2025Stable cost base despite portfolio growth and inflationTotal shareholder return 2025 of +51%Proposed dividend for 2025 at € 1.30 per share (+4%)Outlook 2026 direct result per share € 1.85-1.95 Attachment
LHV Groupi 2025. aasta IV kvartali ja 12 kuu auditeerimata majandustulemused 2025. aasta lõpus näitasid LHV Groupi deposiitide kui ka laenuportfelli mahud väga tugevat kasvu. 2025. aastal mõjutas LHV Groupi tulude dünaamikat kogu aasta väldanud intressikeskkonna muutus, mis avaldas survet intressituludele ning teiselt poolt survestas intressikulusid tugev konkurents hoiuste turul. Hea kliendiaktiivsuse kasv ja teenustasutulu aitasid neto intressitulu langust osaliselt tasakaalustada. IV kvartalis oli näha juba neto intressitulu kasvu võrreldes eelnevate kvartalitega. AS LHV Group teenis 20...
Santhera Appoints Stifel as Corporate Finance Advisor Pratteln, Switzerland, February 10, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announced the appointment of Stifel Nicolaus Europe Limited (“Stifel”) as corporate finance advisor with a focus on capital markets and international institutional investors. Swiss based Octavian AG (“Octavian”) will continue to act as corporate finance advisor to the Company, working alongside Stifel to help broaden investor reach. About SantheraSanthera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the developmen...
Santhera ernennt Stifel zum Finanzberater Pratteln, Schweiz, 10. Februar 2026 – Santhera Pharmaceuticals (SIX: SANN) gab heute die Ernennung von Stifel Nicolaus Europe Limited (“Stifel”) zum Finanzberater mit Schwerpunkt auf Kapitalmärkten und internationalen institutionellen Anlegern bekannt. Die in der Schweiz ansässige Octavian AG (“Octavian”) wird weiterhin als Corporate-Finance-Berater des Unternehmens fungieren und gemeinsam mit Stifel daran arbeiten, den Kreis der Investoren zu erweitern. Über SantheraSanthera Pharmaceuticals (SIX: SANN) ist ein Schweizer Spezialpharmaunternehmen, ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.